An ambulatory pH recorder (Sandhill, Littleton, CO) was used to assess the reflux events in the esophagus. After Vol. 234 • No. 2 Cellular Proliferation in Barrett's Esophagus * Chi square, statistical value for Kruskal-Wallis test; F, statistical value for one-way analysis of variance. Further comparison of each pair (Nemenyi test for Kruskal-Wallis and least significant difference for analysis of variance): † between gastric type and intestinal type without dysplasia, P Ͻ .05; ‡ between intestinal type without and with dysplasia, P Ͻ .05; § between gastric type and intestinal type with dysplasia, P Ͻ .05.
Objective
To assess proliferation in the columnar-lined esophageal mucosa before and after antireflux surgery.
Summary Background Data
Intestinal metaplasia persists in Barrett's mucosa after reflux control. It remains at risk for uncontrolled cellular proliferation and adenocarcinoma formation.
Methods
Forty-five patients with Barrett's esophagus had a mean follow-up of 4 years after a Collis-Nissen gastroplasty. Proliferative activity was assayed immunohistochemically for Ki-67 expression in 73 preoperative and 176 postoperative biopsies. Correlation with manometric and 24-hour pH results was obtained.
Results
The Collis-Nissen gastroplasty restored the median lower esophageal sphincter gradient from 5.5 mmHg before surgery to 14.5 mmHg at 24 months and 12.9 mmHg at 48 months after surgery. The median esophageal acid exposure was reduced from 8% to 1% and 1% of recording time, respectively. The median Ki-67 labeling index increased from 28.5% before surgery to 36.1% at 12 to 23 months. It returned to preoperative level (26.9%) at 24 to 47 months. After surgery, abnormal intraesophageal acid exposure was documented in 12 patients but could not be correlated with sphincter pressure. After surgery, the pattern of proliferation in patients with acid exposure less than 4% in their esophagus showed significant differences when compared with the proliferation pattern of patients where abnormal intraesophageal acid exposure was recorded. New present dysplasia was observed only in patients with abnormal acid exposure.
Conclusions
In Barrett's mucosa, from preoperative values, proliferation peaked early after surgery and then decreased to preoperative levels. Despite sphincter restoration and global reflux control, abnormal esophageal acid exposure persisted in 12 patients. Patients with abnormal esophageal acid exposure displayed more proliferation and more dysplasia.
Barrett's esophagus (BE) is a condition in which the normal squamous epithelium of the distal esophagus is replaced by a metaplastic intestinal epithelium as a conse-quence of long-standing gastroesophageal reflux disease. 1 BE occurs in 5% to 10% of patients with chronic gastroesophageal reflux and is associated with a 30-to 125-fold excess risk of developing esophageal adenocarcinoma. [2] [3] [4] The columnar-lined mucosa is a healing response to esophageal injury. It has been suggested that components present in the reflux material damage the squamous epithelium, resulting in a metaplastic process that alters the differentiation process of exposed multipotential stem cells, leading to a mucus-secreting phenotype. 5 Patients with BE show weak lower esophageal sphincter (LES) pressures, excessive acid and duodenal content reflux, poor esophageal contraction and propulsion, and defi-cient refluxate clearing capacity. 6 -9 The importance and synergy of concomitant duodenal content and acid reflux in generating complications in the columnar mucosa (ulcer, stricture, and dysplasia) have been emphasized by Attwood et al 10 and Stein et al. 11 The mainstay of modern medical therapy for severe gastroesophageal reflux disease and associated BE is aggressive suppression of gastric acid through the administration of proton pump inhibitors (PPIs). 12, 13 However, patients with BE often exhibit pathologic levels of acid reflux, even during therapy with PPIs at doses that eliminate symptoms of gastroesophageal reflux. 14, 15 In two recent studies, medical acid suppression failed to reduce esophageal bile exposure to normal values. 11, 16 In contrast, similar to the well-described effect of Nissen fundoplication on acid gastroesophageal reflux, the antireflux procedure also results in normalization of esophageal bile exposure. 11 Chronic reflux esophagitis might be expected to predispose to cancer by increasing the turnover and proliferation of metaplastic epithelial cells. Therefore, some authors believe that preventing reflux may abrogate the continual irritation of the metaplastic mucosa, allowing the cells to move from an actively proliferating state into a quiescent state. 17 In an ex vivo BE culture model, Fitzgerald et al 18 showed that pulses of acid exposure increase proliferation. This suggested that acid-suppressive therapy needs to be powerful enough to eliminate any acid pulses and inhibit any cell proliferation, thus allowing a more differentiated state in BE epithelia. More recent studies have shown that medium-term PPI therapy (Ͻ6 months) may decrease epithelial proliferation in BE and promote stabilization of the intestinal phenotype. 19, 20 Whether this stabilization reduces the risk of malignant progression remains unknown. The long-term effects of medical acid suppression or antireflux surgery on the proliferative activity in the metaplastic mucosa are not well documented. Some studies suggest that antireflux surgery, by controlling both components of the reflux, acid and duodenal, might reduce the risk of cancer in BE. [21] [22] [23] There are several markers available to measure cellular proliferation: bromodeoxyuridine incorporation, tritiated thymidine incorporation, proliferative cell nuclear antigen (PCNA), and Ki-67 nuclear antigen. 24 The bromodeoxyuridine and tritiated thymidine label the same cohort of cells to establish the S-phase labeling index, and both are regarded as the gold standard for cell proliferation studies. 25 However, these techniques require incubation of fresh tissue, thus precluding the study of biopsy material not already treated with the reagent. 26 Ki-67 is a nuclear antigen present in proliferating cells (G 1 , S, G 2 , and M phases) but absent in resting cells (G 0 ). Numerous studies have shown a good correlation between Ki-67 immunoreactivity and bromodeoxyuridine incorporation in assessing cell proliferation. 25, 27 In 1991, Jankowski et al 28 first studied the Ki-67 labeling index in BE. They reported that the intestinal type of Barrett's mucosa showed the highest Ki-67 labeling index when compared with other types of Barrett's mucosa cells. More-over, Hong et al, 29 using the same technique, found that the Ki-67 labeling index correlated with the degree of dysplasia in BE.
The aim of this study is to investigate, using Ki-67 immunohistochemistry, the proliferative behavior of Barrett's intestinal metaplasia over a long period after antireflux therapy and to assess the impact of such therapy on the rate of dysplasia.
METHODS

Patient Population
From January 1989 through December 1997, 45 patients with BE underwent assessment of their columnar mucosa proliferative activity before and after antireflux surgery. The operation performed was an elongation gastroplasty with a total fundoplication (Collis-Nissen gastroplasty). Postoperative follow-up was obtained at intervals of 12 months. There were 38 men and 7 women, with a mean age of 53.5 years (range . Their average height was 170 cm (5.6 ft) and their mean weight was 75.8 kg (167 lb). The duration of reflux symptoms ranged from 3 to 37 years (mean 13). Before surgery, all patients had at least 6 months of acid suppression with PPIs and the occasional association of prokinetic agents. The mean postoperative follow-up was 4.0 years (range 1-9). In seven patients a previous Nissen fundoplication had failed 3 to 19 years after their initial operation. Pre-and postoperative investigations included esophageal manometry, 24-hour pH monitoring, endoscopy, and Ki-67 immunohistochemistry.
Manometry
Fasting patients were assessed using a four-lumen polyvinyl motility catheter (Mui Scientific, Mississauga, Canada). Each lumen had an internal diameter of 0.8 mm with the orifices opening at 5-cm intervals and radially oriented at 90°. The recording tube was introduced through the nose and connected to external transducers placed at head level. Pressures were preamplified and recorded on a four-channel physiograph. Constant low-volume perfusion (0.3 mL/min for each channel) was obtained by a pneumohydraulic perfusion system using 776 mmHg (15 psi) of pressure for both the esophageal body and sphincters. Transducers were calibrated before and after each study, using atmospheric pressure as a zero baseline. Ten wet swallows of 2 mL water were given to the patient while pressures were recorded in each of four specific esophageal areas: the upper esophageal sphincter, the proximal and distal half of the esophageal body, and the LES area. LES recording was performed using a stationary pull-through technique. calibration, the antimony electrode was placed 5 cm above the gastroesophageal junction previously identified and localized by manometry. A pH less than 4 was interpreted as acid reflux. Results were computed over a 24-hour period. The total number of reflux episodes, episodes of reflux with a duration greater than 5 minutes, total time of acid exposure (in minutes), and total percentage of acid exposure over time were the retained parameters for this report.
Endoscopy and Biopsy
Endoscopic examinations were performed using a videomonitoring system (Olympus, GIF-130, Olympus Canada, Toronto). Mucosal lesions were classified using Armstrong et al's MUSE system (metaplasia, ulcer, stricture, and erosion). 30 The distance of the proximal limit of the columnar mucosa from the incisors was recorded. The level at which the tubular esophagus joined the regular rugal folds of the gastric cavity was subsequently recorded. The length of the columnar-lined mucosa was computed from these observations. The biopsy specimens were obtained by four-quadrant, multiple biopsies at 2-cm intervals within this mucosal area and were fixed in 3.7% formalin immediately. Histopathologic diagnosis on sections stained with hematoxylin and eosin was done independently by two pathologists (L.G., C.H.). The diagnosis of BE was based on the presence of intestinal-type goblet cells in at least one biopsy sample from the abnormal mucosa in the lower esophagus, irrespective of its length. To ascertain the presence of intestinal goblet cells, alcian blue staining was regularly performed. The diagnosis of dysplasia followed Riddell's criteria. 31 The same biopsy specimens were used for Ki-67 immunohistochemistry.
Ki-67 Immunohistochemistry
Serial sections were cut at 5 m thick, mounted on Superfrost/Plus glass slides (Fisher Scientific, Portsmouth, NH). Tissues were deparaffinized in xylene for 30 minutes, rehydrated with graded ethanol washes (100 -70%), and washed in phosphate-buffered saline (PBS). Endogenous peroxidase activity was blocked by immersing the tissue in 3% aqueous hydrogen peroxide for 10 minutes. After being rinsed in PBS, the tissues were placed in citric acid buffer (10 mmol/L, pH 6.0) and heated to 80°C in a 600-W microwave oven for 20 minutes. The slides were cooled to room temperature and washed in PBS. The tissues were blocked for nonspecific binding with 10% horse serum for 15 minutes, then incubated for 1 hour with primary antibody to Ki-67 (MIB-1, Immunotech, Marseille, France) in 1:50 dilution. After three successive 5-minute washes with PBS, tissues were treated by biotinylated goat-antimouse secondary antibody (1:200 dilution) for 40 minutes. Sections were then rinsed in PBS for 5 minutes ϫ 3 and incubated with a 1:400 dilution of peroxidase-conjugated streptavidin avidinbiotin complex (LSAB Production, DAKO, Canada) for 30 minutes. After three further 5-minute washes in PBS, the chromogen, 3.3'-diaminobenzidine tetrahydrochloride (DAB, 5 mg/10 mL PBS), with 0.05% hydrogen peroxide was applied for 15 minutes. The tissues were then rinsed in distilled water for 5 minutes and counterstained with hematoxylin (100%) (Gill 11 formula) and mounted with glass coverslips with Permount (Fisher Scientific). All antibody reactions were performed at room temperature in humidity chambers. An NCL-H630 colon carcinoma cell line was used as a positive control. The negative control was done after the above procedure, omitting the primary antibody MIB-1.
The quantification of MIB-1 staining was performed by counting the Ki-67 labeling index using the light microscope. The percentage of the Ki-67-positive cells (with dark brown-stained nuclei) was computed in each crypt zone. Only well-oriented crypts were used for this counting. Each crypt was divided into four zones: luminal surface, upper crypt, lower crypt, and underlying glandular zone. The upper and lower crypts were divided halfway from the surface down to the bottom of the crypt, as proposed by Hong et al 29 (Fig. 1) .
Five crypts per specimen were counted whenever possible. The Ki-67 labeling index was determined on each crypt zone by one of the authors (C.H.) without knowledge of the clinical information and research design. The total Ki-67 labeling index represented the mean Ki-67-positive nuclei within each crypt.
Statistical Analysis
Categorical data were expressed as proportion and analyzed by the chi-square test or the Fisher exact probability test. Parametric data were presented as median (interquartile range). For multiple comparisons, the Kruskal-Wallis test or the Friedman test was applied as appropriate for skewed data and analysis of variance for normally distributed data. To compare the two groups of BE patients (with or without postoperative acid exposure), the Mann-Whitney test or the Student t test was used. The Spearman rank-order correlation or the Pearson correlation test was used as appropriate to relate acid exposure with LES gradient, as well as the Ki-67 labeling index before and after surgery. The statistical values are reported. A two-tailed exact probability value is presented unless it was greater than 0.2 or less than 0.001. P Ͻ .05 was considered statistically significant. The statistical analysis was performed by SPSS 7.5 for Windows (SPSS Inc., Chicago, IL).
RESULTS
There were no postoperative deaths. All 45 patients completed long-term clinical follow-up.
Esophageal Manometry and 24-hour pH Monitoring
Functional results for the whole series of the patients were detailed in our previous publication. 9 Before surgery, esophageal acid exposure could be correlated significantly with LES gradient ( Fig. 2A) . After surgery, despite global acid control and a significant reduction in mucosal damage, 12 patients still showed an abnormal acid exposure (Ն4% of the time) in the esophagus. Quantification of the acid exposure could not be correlated with the LES gradient ( Fig. 2B) .
For the 15 patients who completed preoperative, 0 to 23 months, and 24 to 47 months observations, results are reported and compared with the Ki-67 labeling index in Table 1 .
Endoscopy and Biopsies
From the 45 patients, 73 mucosal biopsy samples were obtained before surgery and 176 were taken after surgery. Thirty-four patients had countable MIB-1 staining from 38 specimens before surgery and 35 patients had countable MIB-1 staining from 87 specimens after surgery. On average four crypts per section (two crypts for each in 14 sections, three crypts in 48 sections, four crypts in 83 sections, and five crypts in 65 sections) were identified with well-oriented crypt structure. A total of 1,081 crypt cells (range 265-2,762) per section were counted for the Ki-67 labeling index, which gave an average of 279 cells per crypt (range 105-690). No regression of BE could be identified. In 18 patients, areas of squamous reepithelialization were documented; in 11 of them, biopsies of these areas revealed remaining intestinal metaplasia underneath foci of squamous cell reepithelialization. Before surgery, eight patients showed low-grade dysplasia; for six of them, the dysplasia could no longer be seen in the biopsies taken after surgery.
After surgery, new low-grade dysplasia could be documented in four patients. All patients with newly documented dysplasia were in the subgroup showing abnormal postoperative acid exposure (4/12 vs. 0/30, chi square ϭ 7.523, P ϭ .006). Two patients in this subgroup had, at endoscopy, an intrathoracic migration of the repair, a flattened fundoplication on retroflexion examination, or a low LES gradient with mucosal erosions at the mucosal junction. Table 1 shows the results of the Ki-67 labeling index in Barrett's intestinal metaplasia, together with the manometry and 24-hour pH monitoring data in the subgroup of patients in whom disease was assessed before surgery, at 0 to 23 months, and at 24 to 47 months.
Ki-67 Immunohistochemistry
Twenty-six patients had countable intestinal metaplasia biopsies and documented reflux control after surgery (acid exposure Ͻ4% of total recording time). Ten of 12 patients showed both countable intestinal metaplasia biopsies and persistent acid exposure in the esophagus after surgery (two patients with abnormal acid exposure in the esophagus did Table 2 details the Ki-67 labeling index results in patients with or without postoperative abnormal acid exposure, and Figure 3 plots the correlation between postoperative acid exposure and the Ki-67 labeling index in each crypt zones.
When patients have persistent abnormal acid exposure in the esophagus, there is a significant increase in the cellular proliferation of their columnar-lined intestinal metaplasia cells. The Ki-67 labeling index is higher on the mucosal surface, in the upper crypt, and in the lower crypt. When the acid exposure is in the normal range, a significant decrease in cellular proliferation can be seen on the mucosal surface and in the upper and lower crypts (Fig. 4) .
The proliferative activity, when measured in the gastric metaplasia mucosa, is identified mostly in the lower crypt and glandular zone. The Ki-67 labeling index shows a similar pattern in the intestinal metaplasia mucosa, but the proliferative activity is significantly higher. The Ki-67 labeling index is further increased when dysplasia is present and this proliferative activity then expands toward the upper crypt and mucosal surface ( Table 3 ).
DISCUSSION
To our knowledge, this is the first study that assessed, over a long period, the proliferative activity in the columnar-lined esophagus of patients after antireflux surgery. Our findings suggest overall stabilization, in time, of the proliferative activity in the metaplastic mucosa after antireflux surgery. Persistent esophageal abnormal acid exposure after surgery, however, predisposes to epithelial cell hyperproliferation and the subsequent appearance of dysplasia.
The intestinal phenotype of BE represents an unstable epithelium that is at risk to become dysplastic. Increased epithelial proliferation is considered an early biologic event in the stepwise progression toward carcinoma formation in BE. 29, [32] [33] [34] Accumulation of multiple genetic abnormalities leads to hyperproliferation, genomic instability, and clonal expansion. 35 Cell proliferation in BE and dysplasia have been assessed using different markers such as PCNA and Ki-67, which can be detected immunohistochemically with nuclear staining. In normal gastric-type mucosa and in specialized-type epithelium without dysplasia, Ki-67-immunoreactive cells were localized at the base of the crypts and glandular zones, which correspond to the naturally occur- ring proliferative zone. We observed a higher Ki-67 labeling index in specialized-type columnar metaplasia compared with gastric-type epithelium. These findings agree with the results of previous reports that have shown an increase in the overall proportion of proliferating cells in intestinal-type Barrett's mucosa compared with gastric-type Barrett's metaplasia. 29, 34, 36 In epithelial dysplasia, proliferation occurs throughout the crypt: Ki-67-positive cells appear not only in the glandular zone but also in the upper crypt and on the surface epithelium. Our observations on Ki-67 staining agree with the results reported by Hong et al, 29 who showed a shift of increased proliferative activity toward the upper crypt and the luminal surface with increasing severity of dysplasia. These changes reflect a disturbance of the normal cell cycle control mechanism, leading to continued DNA synthesis and replacement of differentiated cells by immature proliferating cells near the surface epithelium. These cells, which have lost the ability to exit the cell cycle, may be more susceptible to genetic alterations, allowing clonal expansion of cells associated with dysplasia. 37 Recently, Whittles et al 38 found a decrease in apoptosis in the upper crypt and luminal surface when dysplasia and adenocarcinoma are present as opposed to when metaplasia alone is seen. This may lead to proliferation of cells with DNA mutations that would have been otherwise eliminated by apoptosis.
Several studies have reported that chronic therapy with PPIs can produce partial regression in BE and the appearance of squamous islands. 39, 40 The same phenomenon has also been described after antireflux surgery. 41 In our series, 18 of 45 patients with BE developed areas of squamous reepithelialization. However, more than 50% of these areas had intestinal metaplasia underneath the squamous epithelium. Sharma et al 42 reported that in one third of biopsy samples taken from squamous epithelium islands, intestinal metaplasia was still present underneath. This is not a good or a bad thing. We see those squamous islands as a healing process. These histologic changes in Barrett's epithelium do not suggest regression, because intestinal metaplasia persists with its inherent risk of malignant transformation. 43, 44 True regression theoretically eliminates cancer risk, whereas overriding mucosa may simply obscure the early detection of potentially treatable lesions. Squamous reepithelialization in BE is not metaplasia regression and warrants continued surveillance.
The role of both aggressive medical treatment and anti- Biopsy specimens of BE were analyzed for villin, a differentiation marker, and PCNA, a proliferation marker, before and 6 months after normalization of intraesophageal pH with lansoprazole. Six months later, PCNA expression decreased and villin expression increased in 24 patients whose intraesophageal pH normalized. Fifteen patients had persistent abnormal intraesophageal acid reflux without change in villin or PCNA expression. They concluded that effective intraesophageal acid suppression favors differentiation and decreases proliferation. Further, one group has reported that nuclear cyclin D1 protein expression, notably associated with dysplasia and carcinoma in BE, may be reduced by treatment with PPIs. 45 Our results show that proliferative activity in specialized intestinal metaplasia increases early after antireflux surgery. This might be an early response to surgical manipulation. Over time, proliferation decreases to preoperative levels. During longer follow-up (mean 4 years), antireflux surgery does achieve an overall stabilization of the proliferative activity in BE. Despite global acid control, however, the presence of abnormal intraesophageal acid was still documented in 12 patients (26.6%). We cannot say whether this acid represents persistent reflux or esophageal acid secretion by the fundic-type metaplasia where abundant parietal cells were observed. The acid secretion by Barrett's gastric-type mucosa was documented previously by Hershfield et al. 46 Food stagnation and fermentation may also result in creating an acid environment. 47 Barrett's mucosa patients with abnormal postoperative acid exposure reveal increased proliferative activity on the surface and upper crypt. Complete normalization of intraesophageal pH results in significantly less proliferative activity in the same crypt zones. It is worth noting that four new cases of low-grade dysplasia were diagnosed after surgery, and all these cases were seen in the subgroup of patients showing abnormal acid exposure. This observation supports the hypothesis that maintained epithelial cell hyperproliferation resulting from uncontrolled reflux or acid secretion in the esophagus elicits an environment that favors the development of dysplasia. Some studies have investigated whether BE progresses to dysplasia after surgical treatment of reflux disease. The results of two prospective studies and one randomized study suggest that patients treated by antireflux surgery have a reduced risk of developing dysplasia. [21] [22] [23] In particular, Ortiz et al 22 reported that patients in whom antireflux surgery proved effective showed no dysplastic change. Conversely, dysplasia was observed in five patients from the group undergoing medical treatment. Five of 32 patients undergoing a Nissen procedure had recurrent reflux on 24-hour pH studies (15.6%). One of these patients developed high-grade dysplasia 7 years after a failed Nissen procedure. In our present study, no patient with an effective antireflux procedure was documented to have progression of dysplastic changes during follow-up. Of interest, six of eight cases of dysplasia detected before surgery were not seen in the biopsy samples taken after surgery. A recent study observed that successful antireflux surgery can produce stabilization or apparent improvement in dysplasia in patients with BE. 41 We must acknowledge that biopsy sampling error during endoscopic surveillance as a result of the multifocal distribution of dysplasia in BE makes the assessment of the natural history of dysplasia very difficult. Despite systematic four-quadrant biopsies, it is known that significant dysplasia is found in only 4% of the mucosal surface. 4 We tried to reduce this problem by taking multiple biopsy samples along the whole of the metaplastic surface and around the whole circumference. Future studies with larger patient samples and using new promising methods to detect dysplasia are necessary to confirm the effects of antireflux surgery on metaplasia progression to dysplasia in BE. 48 In summary, our observations suggest that the proliferative activity of intestinal metaplasia cells is more active than the gastric metaplasia cells in BE. Antireflux operations result in an immediate early increase in the proliferative activity of the abnormal epithelium. This increase in cell division decreases progressively with time after surgery. Four years after surgery, proliferation returns to the early preoperative status. In patients in whom abnormal acid exposure persists, independently of its origin, increased cellular proliferation is seen with expansion of this activity toward the surface of the metaplastic epithelium. Dysplasia is identified only in patients in whom abnormal acid exposure is present in the esophagus. BE patients, even after antireflux surgery, should be part of a surveillance program to rule out persistent acid exposure, detect dysplasia at an early stage, and try to reduce the risk of progression toward malignancy. Data are expressed as median (interquartile range).
